Genomic Integration of High-Risk HPV Alters Gene Expression in Oropharyngeal Squamous Cell Carcinoma

High-risk HPV (hrHPV) is the leading etiologic factor in oropharyngeal cancer. HPV-positive oropharyngeal tumors generally respond well to therapy, with complete recovery in approximately 80% of patients. However, it remains unclear why some patients are nonresponsive to treatment, with 20% of patients recurring within 5 years. In this study, viral factors were examined for possible clues to differences in tumor behavior. Oropharynx tumors that responded well to therapy were compared with those that persisted and recurred. Viral oncogene alternate transcripts were assessed, and cellular sites of viral integration were mapped and sequenced. Effects of integration on gene expression were assessed by transcript analysis at the integration sites. All of the tumors demonstrated active viral oncogenesis, indicated by expression of HPV E6 and E7 oncogenes and alternate E6 splicing. In the responsive tumors, HPV integration occurred exclusively in intergenic chromosome regions, except for one tumor with viral integration into TP63. Each recurrent tumor exhibited complex HPV integration patterns into cancer-associated genes, including TNFRSF13B, SCN2A, SH2B1, UBE2V2, SMOC1, NFIA, and SEMA6D. Disrupted cellular transcripts were identified in the region of integration in four of the seven affected genes. Implications: Integration of transcriptionally active hrHPV into cellular intergenic regions associates with tumor behavior by altering gene expression. Mol Cancer Res; 14(10); 941–52. ©2016 AACR.

[1]  Jordi Giralt,et al.  Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. , 2010, The Lancet. Oncology.

[2]  E. Boccardo.  HPV-Mediated Genome Instability: At the Roots of Cervical Carcinogenesis , 2010, Cytogenetic and Genome Research.

[3]  A. Eisbruch,et al.  High-risk human papillomavirus detection in oropharyngeal, nasopharyngeal, and oral cavity cancers: comparison of multiple methods. , 2013, JAMA otolaryngology-- head & neck surgery.

[4]  A. Merlo,et al.  SMOC1 is a tenascin-C interacting protein over-expressed in brain tumors. , 2011, Matrix biology : journal of the International Society for Matrix Biology.

[5]  Jianliu Wang,et al.  Dysregulation of host cellular genes targeted by human papillomavirus (HPV) integration contributes to HPV‐related cervical carcinogenesis , 2015, International journal of cancer.

[6]  S. Wolf,et al.  Multiplex Identification of Human Papillomavirus 16 DNA Integration Sites in Cervical Carcinomas , 2013, PloS one.

[7]  L. Turek,et al.  P16INK4a expression, human papillomavirus, and survival in head and neck cancer. , 2008, Oral oncology.

[8]  Julia Jellusova,et al.  Signaling by the tumor necrosis factor receptor superfamily in B‐cell biology and disease , 2011, Immunological reviews.

[9]  A. Catalano,et al.  The plexin-A1 receptor activates vascular endothelial growth factor-receptor 2 and nuclear factor-kappaB to mediate survival and anchorage-independent growth of malignant mesothelioma cells. , 2009, Cancer research.

[10]  C. Tsien,et al.  EGFR, p16, HPV Titer, Bcl-xL and p53, sex, and smoking as indicators of response to therapy and survival in oropharyngeal cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  A. Poustka,et al.  Integration of human papillomavirus type 6a DNA in a tonsillar carcinoma: chromosomal localization and nucleotide sequence of the genomic target region. , 1994, Cancer research.

[12]  Chandra Sekhar Pedamallu,et al.  Characterization of HPV and host genome interactions in primary head and neck cancers , 2014, Proceedings of the National Academy of Sciences.

[13]  K. Yamanegi,et al.  Splicing of a cap-proximal human Papillomavirus 16 E6E7 intron promotes E7 expression, but can be restrained by distance of the intron from its RNA 5' cap. , 2004, Journal of molecular biology.

[14]  C. Tsien,et al.  Chemoselection as a strategy for organ preservation in advanced oropharynx cancer: response and survival positively associated with HPV16 copy number. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  Z. Xiong,et al.  Ion channels as targets for cancer therapy. , 2011, International journal of physiology, pathophysiology and pharmacology.

[16]  E. Giraudo,et al.  The role of semaphorins and their receptors in vascular development and cancer. , 2013, Experimental cell research.

[17]  M. von Knebel Doeberitz,et al.  Detection of integrated papillomavirus sequences by ligation‐mediated PCR (DIPS‐PCR) and molecular characterization in cervical cancer cells , 2001, International journal of cancer.

[18]  M. Gillison,et al.  Clinical implications of human papillomavirus in head and neck cancers. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  Jeremy MG Taylor,et al.  Response to therapy and outcomes in oropharyngeal cancer are associated with biomarkers including human papillomavirus, epidermal growth factor receptor, gender, and smoking. , 2007, International journal of radiation oncology, biology, physics.

[20]  Lars Jansen,et al.  Non-Random Integration of the HPV Genome in Cervical Cancer , 2012, PloS one.

[21]  Lajos Pusztai,et al.  DNA repair gene patterns as prognostic and predictive factors in molecular breast cancer subtypes. , 2013, The oncologist.

[22]  E. Speel,et al.  Viral load, gene expression and mapping of viral integration sites in HPV16‐associated HNSCC cell lines , 2015, International journal of cancer.

[23]  S. Duensing,et al.  Genomic instability and cancer: lessons learned from human papillomaviruses. , 2011, Cancer letters.

[24]  S. Gollin,et al.  Mapping and analysis of HPV16 integration sites in a head and neck cancer cell line , 2004, International journal of cancer.

[25]  David I. Smith,et al.  Acquisition of High-Level Chromosomal Instability Is Associated with Integration of Human Papillomavirus Type 16 in Cervical Keratinocytes , 2004, Cancer Research.

[26]  E. Leo,et al.  Molecular analysis of HPV 16 E6I/E6II spliced mRNAs and correlation with the viral physical state and the grade of the cervical lesion , 2009, Journal of medical virology.

[27]  M. M. Pater,et al.  Splice sites of human papillomavirus type 16 E6 gene or heterologous gene required for transformation by E7 and accumulation of E7 RNA , 1995, Journal of medical virology.

[28]  Yang Ke,et al.  Comprehensive mapping of the human papillomavirus (HPV) DNA integration sites in cervical carcinomas by HPV capture technology , 2015, Oncotarget.

[29]  F. E. Yoder,et al.  Chromosome fragile sites. , 1985, Cancer genetics and cytogenetics.

[30]  Trevor J Pugh,et al.  Landscape of genomic alterations in cervical carcinomas , 2013, Nature.

[31]  D. Ma,et al.  The physical state of HPV16 infection and its clinical significance in cancer precursor lesion and cervical carcinoma , 2008, Journal of Cancer Research and Clinical Oncology.

[32]  E. Klimov,et al.  Human papilloma viruses and cervical tumours: mapping of integration sites and analysis of adjacent cellular sequences , 2002, BMC Cancer.

[33]  D. Merico,et al.  Transcriptional Network of p63 in Human Keratinocytes , 2009, PloS one.

[34]  F. Feng,et al.  Tobacco Use in Human Papillomavirus–Positive Advanced Oropharynx Cancer Patients Related to Increased Risk of Distant Metastases and Tumor Recurrence , 2010, Clinical Cancer Research.

[35]  T. Ried,et al.  Genome-wide analysis of HPV integration in human cancers reveals recurrent, focal genomic instability , 2014, Genome research.

[36]  T. Carey,et al.  UM‐SCC‐104: A New human papillomavirus‐16–positive cancer stem cell–containing head and neck squamous cell carcinoma cell line , 2012, Head & neck.

[37]  W. Westra,et al.  Distinct risk factor profiles for human papillomavirus type 16-positive and human papillomavirus type 16-negative head and neck cancers. , 2008, Journal of the National Cancer Institute.

[38]  L. Turek,et al.  Analysis of the integration of human papillomaviruses in head and neck tumours in relation to patients' prognosis , 2016, International journal of cancer.

[39]  S. Costa,et al.  Viral DNA load, physical status and E2/E6 ratio as markers to grade HPV16 positive women for high-grade cervical lesions. , 2007, Gynecologic oncology.

[40]  E. Speel,et al.  Integration of HPV6 and Downregulation of AKR1C3 Expression Mark Malignant Transformation in a Patient with Juvenile-Onset Laryngeal Papillomatosis , 2013, PloS one.

[41]  M. Hori,et al.  Dual roles of Sema6D in cardiac morphogenesis through region-specific association of its receptor, Plexin-A1, with off-track and vascular endothelial growth factor receptor type 2. , 2004, Genes & development.

[42]  Ping Wang,et al.  Identification of genes with a correlation between copy number and expression in gastric cancer , 2012, BMC Medical Genomics.

[43]  S. Vinokurova,et al.  Systematic Review of Genomic Integration Sites of Human Papillomavirus Genomes in Epithelial Dysplasia and Invasive Cancer of the Female Lower Genital Tract , 2004, Cancer Research.

[44]  M. Ustav,et al.  Recombination-Dependent Oligomerization of Human Papillomavirus Genomes upon Transient DNA Replication , 2013, Journal of Virology.

[45]  Shih-hung Huang,et al.  Integration of human papillomavirus correlates with high levels of viral oncogene transcripts in cervical carcinogenesis. , 2011, Virus research.

[46]  P. Howley,et al.  Disruption of either the E1 or the E2 regulatory gene of human papillomavirus type 16 increases viral immortalization capacity. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[47]  J. McCoy,et al.  The E7 Oncoprotein Is Translated from Spliced E6*I Transcripts in High-Risk Human Papillomavirus Type 16- or Type 18-Positive Cervical Cancer Cell Lines via Translation Reinitiation , 2006, Journal of Virology.

[48]  K. Ang,et al.  Human papillomavirus and survival of patients with oropharyngeal cancer. , 2010, The New England journal of medicine.